Scholarly article on topic 'Differential effects of oral and transdermal menopausal hormone therapy on prostacyclin and thromboxane in platelets'

Differential effects of oral and transdermal menopausal hormone therapy on prostacyclin and thromboxane in platelets Academic research paper on "Veterinary science"

Share paper
Academic journal
Physiol Rep
OECD Field of science

Academic research paper on topic "Differential effects of oral and transdermal menopausal hormone therapy on prostacyclin and thromboxane in platelets"

Physiological Reports

Physiological Reports ISSN 2051-817X


Differential effects of oral and transdermal menopausal hormone therapy on prostacyclin and thromboxane in platelets

Limor Raz1, Larry W. Hunter1, Muthuvel Jayachandran1,2, John A. Heit3 & Virginia M. Miller1,2

1 Department of Surgery, Mayo Clinic, Rochester, Minnesota, 55905

2 Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, 55905

3 Department of Internal Medicine (Division of Cardiovascular Diseases), Mayo Clinic, Rochester, Minnesota, 55905


Endothelial function, estrogen, estrone, KEEPS.


Virginia M. Miller, Departments of Surgery,

Physiology and Biomedical Engineering, Mayo

Clinic and Foundation, 200 First Street SW,

Rochester, MN 55905

Tel: (507)-284-2290

Fax: (507)-266-2233


Funding Information

The KEEPS was supported by grants from the Aurora Foundation to the Kronos Longevity Research Institute. Other support came from NIH HL90639, UL1 TR000135 (From the National Center for Advancing Translational Sciences (NCATS). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.), HD65987, AG44170, American Heart Association-Scientist Development Grant, AHA 08-30503Z, American Heart Association Grant-in-Aid, 12GRNT12050147 and the Mayo Foundation.

Received: 19 February 2014; Accepted: 3 March 2014


Menopausal hormone therapies (MHT) may increase thrombotic risk but modulate endothelial function and reduce development of vascular lesions. This study compared effects of MHT on prostanoid-modulated adenosine tri-phosphate (ATP) secretion from platelets in relationship with endothelial reactive hyperemia (RH) index and carotid intima medial thickness (CIMT). Participants were healthy, recently menopausal women of the Kronos Early Estrogen Prevention Study (KEEPS) randomized to one of three treatments: oral conjugated equine estrogen (oCEE, 0.45 mg/day), transdermal 17y8-estra-diol (tE2, 50 ig/day) each with intermittent oral progesterone or placebo pills and patch (PL). Prostacyclin and thromboxane A2 were assessed by quantification of their stable metabolites (6-keto-prostaglandin F1a, 6-k-PGF1a; thromboxane B2, TXB2), using ELISA. Dense granule ATP secretion from activated platelets was determined by bioluminescence; RH and CIMT were determined by fingertip tonometry and ultrasound, respectively. After 48 months of treatment, platelet content of 6-k-PGF1a and TXB2 was significantly lower in oCEE compared to the PL. Inhibition of ATP secretion by exogenous activation of cAMP associated with platelet 6-k-PGF1a (r = -0.41, P = 0.04) and TXB2 (r = 0.71, P = 0.0005) only in the oCEE group. Serum and platelet content of 6-k-PGF1a and TXB2 associated positively in the PL and tE2 groups. Serum 6-k-PGF1a positively associated with RH in the oCEE group (r = 0.73, P = 0.02), while serum TXB2 positively associated with CIMT in the tE2 group (r = 0.64, P = 0.01). Thus, oCEE and tE2 differentially affect prosta-noid-mediated platelet secretory pathways but alone would not account for an increased thrombotic risk for oral MHT. Furthermore, platelet-derived prosta-noids may contribute to RH and vascular remodeling in healthy menopausal

doi: 10.1002/phy2.275

Physiol Rep, 2 (3), 2014, e00275, doi: 10.1002/phy2.275


Estrogenic treatments used to reduce menopausal symptoms carry a label warning of risk for thrombosis with

their use. Further, population-based and multicenter case-control studies provide evidence that oral estrogenic products (either esterified estrogen or conjugated equine estrogen) may carry a small but greater risk (<4%) for

© 2014 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of 2014 | Vol. 2 | Iss. 3 | e00275

thrombotic events such as ischemic stroke, myocardial infarction and venous thromboembolism than transdermal products (Scarabin et al. 1997, 2003; Writing, WGftWsHII 2002; Canonico et al. 2007; Shufelt et al. 2014). This difference between oral and transdermal products reflects, in part, the direct absorption of the estrogens into the enterohepatic circulation (De Lignieres et al. 1986), and thus, a greater effect on production in the liver of proteins associated with coagulation, fibrino-lysis, and inflammation than transdermal products. However, estrogens also affect production of proteins through genomic actions on gene transcription in all nucleated cells including megakaryocytes, the precursors of platelets, and vascular endothelial cells (Elam et al. 1980; Bar et al. 1993; Mikkola et al. 2000; Duckles and Miller 2010). Indeed, estrogen dose-dependently modulates cyclooxy-genase activity and synthesis of prostacyclin (PGI2) and thromboxane A2 (TXA2) from platelets and endothelial cells (Roncaglioni et al. 1979; Chang et al. 1981; Corva-zier et al. 1984; Schmitz et al. 1985; Holmsen 1986; Macdonald et al. 1988; Kahn et al. 1993; Redmond et al. 1994; Bolego et al. 1997; Mikkola et al. 2000; Canonico et al. 2007; Capone et al. 2007). Because the turnover of platelets in humans is about 10-12 day, platelets produced under conditions of either hormone deplete or replete conditions might be expected to differ in their secretory activity and secretome.

PGI2 and TXA2 exert opposing actions on platelet aggregation and vascular reactivity through mechanisms involving cyclic-AMP (Vericel et al. 1988; Ibe et al. 1989; Dogne et al. 2000). In platelets, PGI2 activates adenylate cyclase leading to increased synthesis of cAMP which reduces platelet cytosolic calcium concentration and inhibits platelet activation; TXA2 does the opposite (Dogne et al. 2005). In vascular smooth muscle cells, similar mechanisms regulate smooth muscle contraction, proliferation, and migration (Schror 1993). Thus, their balance is critical to maintain vascular homeostasis.

Previous studies using sexually mature female pigs demonstrated that platelet dense granular ATP secretion increased following oophorectomy but was reduced by oral estrogenic treatments (either conjugated equine estrogen, 17 b estradiol or raloxifene) (Jayachandran and Miller 2002; Jayachandran et al. 2003, 2005a, 2005b). In addition, treatment with oral 17b-estradiol increased the ratio of thromboxane to prostacyclin secreted from collagen-activated platelets which could promote platelet aggregation and vasoconstriction (Lewis et al. 2006). These results suggest that oral estrogen could increase TXA2, decrease PGI2, or both. Similar observations have not been made in platelets from recently menopausal women using MHT. Therefore, the goal of this study was to evaluate and compare how oral conjugated equine

estrogen and transdermal 17 b-estradiol affect the content of PGI2 and TXA2 and secretion of ATP from dense granules in platelets derived from healthy, recently menopausal women. In addition, a second goal was to assess if platelet or serum PGI2 and TXA2 associated with endo-thelial mediated vascular reactivity and vascular remodeling. On the basis of results of the pig experiments outlined above, we hypothesized that: (1) serum levels of prostanoids would reflect their content in platelets, (2) oral estrogenic products would inhibit dense granule ATP secretion, and (3) serum TXA2 would correlate with lower endothelial function, measured by forearm reactive hyper-emia, and increased vascular remodeling, as measured by carotid intima medial thickness (CIMT).

Methods Study design

Participants were a subset of recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS) at Mayo Clinic. KEEPS was a randomized, double-blind, placebo-controlled clinical trial to test whether MHT initiated within 3 years of menopause slowed progression of atherosclerosis, defined by changes in CIMT. Detailed inclusion and exclusion criteria for the KEEPS have been published (Harman et al. 2005). Briefly, exclusion criteria were: coronary arterial calcification score of >50 Agatston Units, smoking over 10 cigarettes per day, BMI >35 kg/m2, history of cardiovascular disease, low-density lipoprotein cholesterol >190 mg/dL, triglycerides >400 mg/dL, blood glucose >126 mg/dL, uncontrolled hypertension (systolic blood pressure >150 mmHg and/or diastolic blood pressure >95 mmHg), current or recent (6 months) use of cholesterol-lowering medications (statins, fibrate, or >500 mg/ day niacin), follicle-stimulating hormone level <35 ng/ mL and estrogen levels >40 pg/mL.

Participants were randomized to one of three treatments: oral conjugated equine estrogen (oCEE, 0.45 mg/ day) plus a placebo transdermal patch, transdermal 17b-estradiol (tE2, 50 ig/day) plus a placebo pill, or placebo (PL) pills and patch, for 48 months. Women in the active treatment groups also received oral micronized progesterone (200 mg) for the first 12 days of each month. Participants were asked to refrain from use of aspirin for 2 weeks prior to collection of blood and platelets.

Serum analytes

After an overnight fast, venous blood was collected into glass tubes without anticoagulants, and centrifuged at 3000 g for 15 min. Aliquots of serum were stored at

—80°C until analysis. Estrone (E1), estradiol (E2), and total testosterone were quantified using high-sensitivity liquid chromatography-tandem mass spectrometry (HLC-MS/MS); sex hormone-binding globulin (SHBG) was quantified by two-site chemiluminescent immunoassay, using the Immulite 2000 SHBG test. Serum PGI2 and TXA2 were examined by quantifying their stable metabolites 6-keto-prostaglandin F1a (6-k-PGF1a) and thromboxane B2 (TXB2), respectively, using ELISA (#KA0294 Abnova, Oxford Biomedical Research, Oxford, MI).

Platelet dense granule ATP secretion

Platelet-rich plasma was prepared from blood collected with trisodium citrate (3.2%) and diluted to 250-500 platelets/iL. Platelet dense granule ATP secretion in response to thrombin receptor agonist peptide (TRAP, 10 imol/L) was measured in the absence or presence of prostaglandin E1 (PGE1; ~500 nmol/L incubation for 10 min at 32°C) (Smith and Owen 1999; Jayachandran et al. 2011) by bioluminescence using premixed luciferin/ luciferase. PGE1 increases platelet cAMP and thereby inhibits dense granule secretion in response to agonists, including TRAP. The degree of inhibition in the presence of PGE1 is a surrogate measure of endogenous activation of cAMP such that the greater the inhibition, the lower the endogenous cAMP activity. Dense body ATP secretion was expressed as attomoles (amoles)/platelet. PGE1 sensitivity was expressed as %inhibition of dense body ATP secretion.

Platelet lysates

Platelet-rich plasma (PRP) was separated from blood an-ticoagulated with hirudin and soybean trypsin inhibitor or sodium citrate and platelet number was quantified by Coulter counter (Jayachandran et al. 2011). Platelet lysate was prepared from washed platelets (Jayachandran and Miller 2002). Platelets were placed in 200 iL lysis buffer [(#0103004-L; RayBioTech, Norcross, GA); with 5 mmol/L TRIS, 0.5% TRITON X100, and a mixture protease inhibitors (serine, cysteine, aspartic proteases and aminopeptidases) (#P8340, Sigma, St. Louis, MO), pH 7.4], passed through a 26-guage needle 8-10 times, then sonicated. Insoluble membrane debris was pelleted by centrifugation at 12,000 g for 5 min. Protein concentration in the lysate (supernatant) was measured (BCA kit #23225, Pierce Biotech, Rockford, IL), then TXA2 and PGI2 were examined by quantifying their stable metabolites TXB2 and 6-k-PGF1a, respectively, using ELISA kits (GenWay Biotech, San Diego, CA and Abnova Oxford Biomedical Research, Oxford, MI, respectively).

Carotid intima medial thickness

Carotid intima medial thickness, the primary outcome of KEEPS, was measured by B-mode ultrasonography (Hodis et al. 2001; Miller et al. 2009).

Endothelial function

Endothelial function was measured using peripheral to-nometry to detect changes in digital pulse volume during reactive hyperemia (EndoPAT, model 2000; Itamar Medical, Ltd., Caesarea, Israel) (Mulvagh et al. 2010). The Reactive Hyperemia Index (RHI) was calculated by dedicated software in the system computer.

Statistical analysis

All data were collected at exit from the study, that is, after 48 months of treatment. Data are presented as mean ± SEM. The number of participants is designated by "n". Differences in the number of samples analyzed in each category reflect insufficient amount of platelet lysate available to perform all of the assays. The ratio of PGI2 to TXA2 could be determined only on samples that had both measurements from the same individual. Platelet lysate concentrations of 6-k-PGF1a and TXB2 approximated normal distribution. Not all participants elected to undergo testing for endothelial reactive hyperemia as this was an ancillary study to the KEEPS protocol and the number of data points reflects only those participants for whom there were measures of PGI2, TXA2, and reactive hyperemia.

A series of linear regression models and Pearson's correlations were used to test associations. Regression coefficients and corresponding P-values were calculated for each model. One-way analysis of variance (ANOVA) was performed for pairwise multiple comparisons of the three treatment groups, followed by Dunnett's or Holm-Sidak post hoc analysis tests; significance was accepted at P < 0.05. Student's t-test was also used to identify differences between two treatment groups.


General characteristics

Clinical characteristics of this subset of KEEPS participants from whom platelets were studied after 48 months of treatment are shown in Table 1.

MHT for 48 months increased serum estrone, 17b-estradiol, and sex hormone-binding globulin compared to PL. Serum estrone was higher with oCEE than with tE2, whereas serum 17b-estradiol was higher with tE2 than

Table 1. Characteristics of KEEPS participants after 48 months of treatment.

Placebo tE2 oCEE

N = 27 N = 22 N = 20


Age (years) 57.1 ± 0.4 57.4 ± 0.6 56.8 ± 0.5

Months past menopause 64.5 ± 1.7 69.8 ± 1.8 65.7 ± 2.4

Cardiovascular risk factors

Waist circumference (cm) 92.6 ± 2.0 84.5 ± 2.7 88.4 ± 3.0

Low-density lipoprotein (mg/dL) 14.0 ± 5.5 108.8 ± 7.4 99.9 ± 7.4*

High-density lipoprotein (mg/dL) 73.3 ± 2.5 73.6 ± 2.6 75.0 ± 2.9

Triglycerides (mg/dL) 90.1 ± 10.4 78.1 ± 7.2 120.3 ± 8.3*

Systolic blood pressure (mmHg) 20.3 ± 2.7 119.9 ± 3.7 120.9 ± 2.7

Fasting glucose (mg/dL) 81.7 ± 1.2 79.6 ± 1.6 81.9 ± 2.5

C-Reactive protein (mg/L) 1.8 ± 0.5 1.4 ± 0.3 2.7 ± 0.6

Platelet count (103/uL) 237.0 ± 8.5 228.1 ± 14.1 232.9 ± 11.8

Vascular imaging

Carotid intima medial thickness (mm) 0.70 ± 0.02 0.75 ± 0.02 0.68 ± 0.02

Reactive hyperemia index 2.50 ± 0.12 2.28 ± 0.16 2.39 ± 0.18

Data are shown as mean ± SEM.

*Denotes statistical significance from other groups, P < 0.05

with oCEE. Sex hormone-binding globulin was significantly greater in the oCEE group compared to tE2 and PL, while total testosterone was similar among groups (Table 2).

Effect of MHT on prostanoids in platelets and serum

Platelet count did not differ significantly among groups (Table 1). Platelet content of 6-k-PGF1a was significantly lower in platelets of women in the oCEE group compared to PL (Fig. 1). TXB2 was variable ranging 30-10950 pg/ mg protein (median 1205.6 pg/mg protein) in the PL group, 54-5929 pg/mg protein (median 278.7 pg/mg protein) in the tE2 group, and 12-3944 pg/mg protein (median 305.0 pg/mg protein) in the oCEE group. Although

Table 2. Hormone levels after 48 months of treatment.

Placebo tE2 oCEE

Hormone N = 27 N = 22 N = 20

Estrone (pg/mL) 22.6 ± 2.0 35.1 ± 2.8 66.1 ± 8.5*

17b-estradiol (pg/mL) 6.4 ± 0.5 30.6 ± 6.0* 13.0 ± 1.6

Sex hormone-binding 50.3 ± 5.3 58.4 ± 5.4 107.1 ± 11.4*

globulin (nmol/L)

Total testosterone 23.1 ± 3.1 25.4 ± 2.5 26.8 ± 2.8


Data are shown as mean ± SEM. *Denotes statistical significance from other groups, P < 0.05.

the mean for TXB2 in the oCEE group was lower than the other groups (961 pg/mg protein in the oCEE group, 1303 pg/mg protein in the tE2 group and 2327 pg/mg protein in the PL group) statistical significance was not realized. The ratio of 6-k-PGF1a to TXB2 was variable also; however, the mean ratio of 6-k-PGF1a to TXB2 was about twice as great in the oCEE compared to tE2 or PL groups (ratio = 1.03, 0.48, 0.38, respectively).

Serum levels of 6-k-PGF1a and TXB2 did not differ among groups (data not shown). There was a positive correlation between serum and platelet levels of 6-k-PGF1a only in the tE2 group (r = 0.80, P = 0.005). Serum levels of TXB2 correlated with platelet content in all groups (Fig. 2). In the PL and tE2 groups, this correlation was positive but in the oCEE group, there was a negative correlation suggesting less-activated release of platelet content of TXB2 during spontaneous aggregation in the oCEE group.

Effects of MHT on platelet dense granule ATP secretion

There were no significant differences in ATP secretion in response to TRAP among treatment groups. However, ATP secretion was inhibited by PGE1 to a greater extent in platelets from women in the PL and tE2 groups compared to oCEE group (Fig. 3). The percent inhibition significantly correlated with platelet content of 6-k-PGF1a and TBX2 only in platelets of women treated with oCEE (Fig. 4).

Figure 1. Content of stable metabolites of prostacyclin (6-k-PGF1a, left panel), and thromboxane (TXB2, middle panel), and their ratio (right panel) in platelets of menopausal women treated either with placebo (PL), transdermal 17b-estradiol (tE2, 50 ig/day), or oral conjugated equine estrogen (oCEE, 0.45 mg/day) for 48 months. Data are shown as means ± SEM, n = unique individuals from whom platelet contents were measured. Asterisk denotes significant difference from PL group, P < 0.05.

Figure 2. Relationships between serum and platelet levels of prostacyclin (6-k-PGF1a) and thromboxane (TXB2) in menopausal women treated with either placebo (PL), transdermal 17b-estradiol (tE2, 50 ig/day), or oral conjugated equine estrogen (oCEE, 0.45 mg/day) for 48 months. Each point represents an individual.

Relationship between platelet or serum prostanoids and vascular parameters

Neither platelet content of 6-k-PGF1a nor TXB2 correlated with RHI or CIMT in any group (data not shown).

However, serum levels of 6-k-PGF1a correlated with RH index only in the oCEE group (r = 0.73, P = 0.02), while TXB2 concentrations in serum significantly correlated (r = 0.64, P = 0.01) with CIMT only in the tE2 group (Fig. 5).

Figure 3. Percent inhibition of dense granule adenosine triphosphate (ATP) secretion from platelets by PGE1. Adenosine triphosphate secretion in response to thrombin receptor agonist peptide (TRAP 10 imol/L) was measured in tandem in paired samples of platelets from each participant in the absence and presence of PGE1 (~500 nmol/L). Data are shown as the percent change in ATP secretion in the presence of PGE1. The greater the inhibition suggests greater increase in cAMP by PGE1. Asterisk denotes significant difference from PL group by Student's t-test, P < 0.05.


This study identified several differences in platelet prostanoid content and dense granule secretion in platelets derived from women using oral conjugated equine estrogen and transdermal 17b estradiol compared to placebo. These differences in platelet characteristics and serum levels of prostanoids affect vascular reactivity and remodeling.

MHT platelet prostanoids and dense granule ATP secretion

Given that the risk of thrombosis is higher with the use of oral compared to transdermal estrogen products, an unexpected finding of the present study was that platelet content of TXA2 a procoagulant prostanoid (Scarabin et al. 1997, 2003; Canonico et al. 2007) trended to be lower in platelets from the oCEE group than the tE2. This difference could reflect either or both increased secretion or decreased production of the prostanoid. Because neither cyclooxygenase activity nor thromboxase synthase activity was measured directly in these platelets, it is not possible to draw a conclusion related to synthesis. However, the negative correlation between serum and platelet TXA2 in the oCEE group argues against the concept that low platelet content resulted from increased secretion during spontaneous aggregation of the platelets in vivo in

this group. However, the positive correlation between serum and platelet levels of TXA2 in the PL and tE2 groups suggest that serum levels may reflect release of TXA2 from platelets during spontaneous aggregation or higher platelet content in these groups.

Platelet cytosolic levels of PGI2 and TXA2 affect platelet dense granule ATP secretion through regulation of cAMP such that increases in cAMP decrease platelet calcium concentration, rendering the platelet relatively less responsive to agonist-stimulated granular secretion (Fig. 6). In the oCEE group, inhibition of ATP secretion by PGE1 was significantly lower than in the other groups. This observation is consistent with the trend to decreased content of TXA2 in platelet from the oCEE group. The percent inhibition of ATP secretion reflected endogenous activation of cAMP such that inhibition decreased in proportion to cytosol PGI2, reflecting high endogenous cAMP activity but increased in proportion to cytosolic TXA2, reflecting low endogenous cAMP activity. ATP secretion did not differ among groups in the absence of PGE1 which may reflect the maximal concentration of TRAP used to stimulate the platelets. Titered release of ATP may have been observed by using lower, threshold, concentrations of the agonist.

Relationship among platelet and serum prostanoids and vascular parameters

Both prostacyclin and thromboxane affect vasomotion and vascular smooth muscle cell proliferation, albeit in opposite ways (Schror 1993). As mentioned above, in the present study as is consistent with other studies, serum levels of thromboxane reflected the platelet levels, but only in the PL and tE2 groups. Serum prostacyclin is thought to reflect that derived from endothelial cells rather than platelets (Callahan et al. 1986). However, in the present study, there was a positive correlation between serum and platelet prostacyclin in the tE2 group suggesting that under some conditions, platelets contribute to circulating levels of prostacyclin.

Release of thromboxane from platelets would be expected to cause vasoconstriction and reduce the RH index. However, RH index did not correlate with serum thromboxane in any group and unexpectedly, RH index correlated to serum prostacyclin only in the oCEE group. RH index will reflect the cumulative actions of other factors such as ATP and 5-hydroxytryptamine released from activated platelets as well as factors released from the endothelium in response to increased shear stress.

Both prostanoids affect smooth muscle proliferation. In the present study, serum levels of prostanoids reflected platelet content only in the tE2 and PL groups. The relationship between serum thromboxane and CIMT

Figure 4. Associations of inhibition of adenosine triphosphate (ATP) secretion with platelet content of stable metabolites of prostacyclin (6-k-PGF1 a) and thromboxane (TXB2) in platelets of menopausal women treated with either placebo (PL), transdermal 17b-estradiol (tE2, 50 ig/day), or oral conjugated equine estrogen (oCEE, 0.45 mg/day) for 48 months. Each point represents an individual.

in the tE2 group is consistent with the concept that platelets are a source of mitogenic factors affecting vascular remodeling. However, thromboxane and prostacy-clin are only two of multiple factors released from platelets which might affect vascular remodeling at sites of endothelial dysfunction. These prostanoids may act synergistically or antagonistically with other growth factors, proteins, or amines associated with immunity, matrix deposition, proteases, and transport (Wijten et al. 2013). Therefore, the change in CIMT over time would likely reflect the collective effect of platelet and blood-borne cytokines as well as mechanical forces on the vascular wall (Jiang et al. 2000).


There are several limitations to this study. First, although both oral conjugated equine estrogen and esterified estrogen may infer a greater risk for thrombosis than transdermal products (Scarabin et al. 1997, 2003; Canonico et al. 2007), the oral and transdermal products used in the

present study were not the same formulation. Therefore, it is not possible to conclude definitively if the route of delivery affected the differences in response compared to the formulation. However, as circulating levels of 17b-estradiol and estrone differed between the treatments groups, the effects observed in the present study most likely reflect effects of the formulation on the platelet characteristics. 17b-estradiol has greater binding affinity for estrogen receptors than does estrone (Bhavnani and Woolever 1991). However, estrone can be metabolized to 17b-estradiol by estradiol 17-b-dehydrogenase 1 which may provide a more prolonged concentration of estrogen and activation of estrogen receptors at the tissue level than might be reflected by serum levels of the hormone (Bagot et al. 2010). With the transdermal product used in this study, premenopausal levels of 17b estradiol were not achieved and further studies would be needed to evaluate a dose effect on the platelet parameters with this product. Oral formulations affect other proteins of the coagulation cascade and inflammatory proteins through actions on their synthesis in the liver (Lacut et al. 2003; Scarabin

Figure 5. Associations of serum prostanoids with RH index (upper panels) and CIMT (lower panels) in menopausal women treated with either placebo (PL), transdermal 17b-estradiol (tE2, 50 ig/day), or oral conjugated equine estrogen (oCEE, 0.45 mg/day) for 48 months. Each point represents an individual.

Figure 6. Schematic depicting regulation of dense granule ATP secretion by cytosolic prostanoids in platelets. AA, arachidonic acid; ATP, adenosine triphosphate; cAMP, cyclic adenosine monophosphate; COX, cyclooxygenase; PAR, protease-activated receptor; PGE1, prostaglandin E1; PG H2, prostaglandin H2; PGI2, prostacyclin; TRAP, thrombin receptor agonist peptide; TXA2, thromboxane; minuses indicate inhibition, pluses indicate activation.

et al. 2003; Eilertsen et al. 2005; Shufelt et al. 2014). Although proteins of the coagulation cascade have yet to be measured in plasma from KEEPS participants, C-reac-tive protein was elevated to a greater extent in the oCEE group. Therefore, the thrombotic risk associated with oral MHT products may not be related to their direct action on platelet responsiveness alone but related to inflammatory risk factors induced by smoking or infection that affect other components of coagulation cascade of an individual.

A second limitation is that the volume of platelet lysate obtained from each participant was variable and in some cases was insufficient to allow analysis of both prosta-noids. In addition, some participants declined measurement of endothelial reactive hyperemia which was an ancillary study to the KEEPS and lowered the number of data points for this parameter.

Finally, baseline levels of serum and platelet prosta-noids were not measured. Thus, the study could evaluate only cross-sectional group effects of treatment rather than paired analysis of treatment effect over time.


This study is the first to compare prostanoid levels in platelets from recently menopausal women using two different formulations of MHT in relationship with platelet secretory function and vascular parameters. Specifically, oCEE had an inhibitory effect on platelet prostanoids, which may affect platelet sensitivity to agonist activation. Serum levels of prostacyclin and thromboxane may not provide an accurate reflection of their concentration in and release from platelets. These effects of MHT on platelet secretion alone may not account for increased thrombotic risk with their use. However, serum prostanoids may affect vascular reactivity and remodeling. Differences in platelet functions with oCEE compared to tE2 may reflect variation in tissue concentrations of 17b-estradiol compared to its metabolites. These metabolites through differential binding affinity for estrogen receptors will modulate genomic actions at the level of the megakaryocytes as well as nongenomic regulation of cytosolic pathways in circulating platelets.


The authors thank the dedicated volunteers participating in this study and coworkers who made this possible including Rebecca Beck, RN, Teresa G. Zais, Robert Litwiller and the staff in the Women's Health Clinic.

Conflict of Interest

None declared. References

Bagot, C. N., M. S. Marsh, M. Whitehead, R. Sherwood, L. Roberts, R. K. Patel, et al. 2010. The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapy. J. Thromb. Haemost. 8:1736-1744. Bar, J., R. Tepper, J. Fuchs, Y. Pardo, S. Goldberger, and J. Ovadia. 1993. The effect of estrogen replacement therapy on platelet aggregation and adenosine triphosphate release in postmenopausal women. Obstet. Gynecol. 81:261-264. Bhavnani, B. R., and C. A. Woolever. 1991. Interaction of ring B unsaturated estrogens with estrogen receptors of human endometrium and rat uterus. Steroids 56:201-210. Bolego, C., A. Cignarella, R. Ruzza, C. Zaarour, E. Messi, M. Zanisi, et al. 1997. Differential effects of low- and high-dose estrogen treatments on vascular responses in female rats. Life Sci. 60:2291-2302. Callahan, K. S., A. Schorer, and J. M. Harlan. 1986. Platelet-derived growth factor does not stimulate prostacyclin synthesis by cultured endothelial cells. Blood 67:131-134.

Canonico, M., E. Oger, G. Plu-Bureau, J. Conard, G. Meyer, H. Levesque, et al. 2007. Hormone therapy and venous thromboembolism among postmenopausal women. Circulation 115:840-845.

Capone, M. L., S. Tacconelli, L. Di Francesco, A. Sacchetti, M. G. Sciulli, and P. Patrignani. 2007. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat. 82:85-94.

Chang, W.-C., J. Nakao, T. Neichi, H. Orimo, and

S.-I. Murota. 1981. Effects of estradiol on the metabolism of arachidonic acid by aortas and platelets in rats. Biochim. Biophys. Acta 664:291 -297.

Corvazier, E., E. Dupuy, A. M. Dosne, and J. Maclouf. 1984. Minimal effect of estrogens on endothelial cell growth and production of prostacyclin. Thromb. Res. 34:303-310.

De Lignieres, B., A. Basdevant, G. Thomas, J. C. Thalabard, C. Mercier-Bodard, J. Conard, et al. 1986. Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration. J. Clin. Endocrinol. Metab. 62:536-541.

Dogne, J. M., X. de Leval, J. Delarge, J. L. David, and B. Masereel. 2000. New trends in thromboxane and prostacyclin modulators. Curr. Med. Chem. 7:609-628.

Dogne, J. M., J. Hanson, and D. Pratico. 2005. Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis. Trends Pharmacol. Sci. 26:639-644.

Duckles, S. P., and V. M. Miller. 2010. Hormonal modulation of endothelial NO production. Pflugers Arch. - Eur. J. Physiol. 459:841-851.

Eilertsen, A. L., E. Hoibraaten, I. Os, T. O. Andersen,

L. Sandvik, and P. M. Sandset. 2005. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis. Maturitas 52:111-118.

Elam, M. B., G. E. Lipscomb, C. M. Chesney, D. A. Terragno, and N. A. Terragno. 1980. Effect of synthetic estrogen on platelet aggregation and vascular release of PGI2-like material in the rabbit. Prostaglandins 20:1039-1051.

Harman, S. M., E. A. Brinton, M. Cedars, R. Lobo, J. E. Manson, G. R. Merriam, et al. 2005. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 8:3-12.

Hodis, H., W. Mack, R. Lobo, D. Shoupe, A. Sevanian, P. Mahrer, et al. 2001. Estrogen in the Prevention of Atherosclerosis. a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 135:939-953.

Holmsen, H. 1986. Platelets and prostaglandins. Cephalalgia 6 (Suppl 4):33-42.

Ibe, B. O., J. R. Falck, A. R. Johnson, and W. B. Campbell. 1989. Regulation of synthesis of prostacyclin and HETEs in human endothelial cells. Am. J. Physiol. 256:C1168-C1175.

Jayachandran, M., and V. M. Miller. 2002. Ovariectomy upregulates expression of estrogen receptors, NOS, and HSPs in porcine platelets. Am. J. Physiol. Heart Circ. Physiol. 283:H220-H226.

Jayachandran, M., W. G. Owen, and V. M. Miller. 2003. Effects of ovariectomy on aggregation, secretion, and metalloproteinases in porcine platelets. Am. J. Physiol. Heart Circ. Physiol. 284:H1679-H1685.

Jayachandran, M., R. Mukherjee, T. Steinkamp, P. LaBreche, M. P. Bracamonte, H. Okano, et al. 2005a. Differential effects of 17b-estradiol, conjugated equine estrogen and raloxifene on mRNA expression, aggregation and secretion in platelets. Am. J. Physiol. Heart Circ. Physiol. 288:H2355-H2362.

Jayachandran, M., A. Sanzo, W. G. Owen, and V. M. Miller. 2005b. Estrogenic regulation of tissue factor and tissue factor pathway inhibitor in platelets. Am J Physiol Heart Circ Physiol 289:H1908-H1916.

Jayachandran, M., R. D. Litwiller, B. D. Lahr, K. R. Bailey, W. G. Owen, S. L. Mulvagh, et al. 2011. Alterations in platelet function and cell-derived microvesicles in recently menopausal women: relationship to metabolic syndrome and atherogenic risk. J. Cardiovasc. Transl. Res. 4:811-822.

Jiang, Y., K. Kohara, and K. Hiwada. 2000. Association between risk factors for atherosclerosis and mechanical forces in carotid artery. Stroke 31:2319-2324.

Kahn, N. N., W. A. Bauman, V. B. Hatcher, and A. K. Sinha. 1993. Inhibition of platelet aggregation and the stimulation of prostacyclin synthesis by insulin in humans. Am. J. Physiol. 265:H2160-H2167.

Lacut, K., E. Oger, G. Le Gal, M.-T. Blouch, J.-F. Abgrall, V. Kerlan, et al., and Investigators atS. 2003. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. Thromb. Haemost. 90:124-131.

Lewis, D. A., M. Avsar, P. LaBreche, M. P. Bracamonte, M. Jayachandran, and V. M. Miller. 2006. Treatment with raloxifene and 17beta-estradiol differentially modulates nitic oxide and prostanoids in venous endothelium and platelets of ovariectomized pigs. J. Cardiovasc. Pharmacol. 48: 231-238.

Macdonald, P. S., M. A. Read, and G. J. Dusting. 1988. Synergistic inhibition of platelet aggregation by endothelium-derived relaxing factor and prostacyclin. Thromb. Res. 49:437-449.

Mikkola, T., L. Viinikka, and O. Ylikorkala. 2000.

Administration of transdermal estrogen without progestin increases the capacity of plasma and serum to stimulate prostacyclin production in human vascular endothelial cells. Fertil. Steril. 73:72-74.

Miller, V. M., D. M. Black, E. A. Brinton, M. J. Budoff, M. I. Cedars, H. N. Hodis, et al. 2009. Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J. Cardiovasc. Transl. Res. 2:228-239.

Mulvagh, S. L., T. Behrenbeck, B. A. Lahr, K. R. Bailey,

T. G. Zais, P. A. Araoz, et al. 2010. Endothelial function and

cardiovascular risk stratification in menopausal women. Climacteric 13:45-54.

Redmond, E. M., M. N. Cherian, and R. C. Wetzel. 1994. 17b-estradiol inhibits flow- and acute hypoxia-induced prostacyclin release from perfused endocardial endothelial cells. Circulation 90:2519-2524.

Roncaglioni, M. C., G. di Minno, I. Reyers, G. De Gaetano, and M. B. Donati. 1979. Increased prostacyclin-like activity in vascular tissues from rats on long-term treatment with an oestrogen-progestagen combination. Thromb. Res. 14:793797.

Scarabin, P. Y., M. Alhenc-Gelas, G. Plu-Bureau, P. Taisne, R. Agher, and M. Aiach. 1997. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: a randomized controlled trial. Arterioscler. Thromb. Vac. Biol. 17:3071-3078.

Scarabin, P. Y., E. Oger, and G. Plu-Bureau. 2003. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 362:428-432.

Schmitz, J. M., P. G. Apprill, L. M. Buja, J. T. Willerson, and W. B. Campbell. 1985. Vascular prostaglandin and thromboxane production in a canine model of myocardial ischemia. Circ. Res. 57:223-231.

Schror, K. 1993. The effect of prostaglandins and

thromboxane A2 on coronary vessel tone-mechanisms of action and therapeutic implications. Eur. Heart J. 14 (Suppl I):34-41.

Shufelt, C. L., C. N. Merz, R. L. Prentice, M. B. Pettinger, J. E. Rossouw, V. R. Aroda, et al. 2014. Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative Observational Study. Menopause 21:260-266.

Smith, R. D., and W. G. Owen. 1999. Platelet responses to compound interactions with thrombin. Biochemistry (Mosc) 38:8936-8947.

Vericel, E., M. Croset, P. Sedivy, P. Courpron, M.

Dechavanne, and M. Lagarde. 1988. Platelets and aging. I-Aggregation, arachidonate metabolism and antioxidant status. Thromb. Res. 49:331-342.

Wijten, P., T. van Holten, L. L. Woo, O. B. Bleijerveld, M. Roest, A. J. Heck, et al. 2013. High precision platelet releasate definition by quantitative reversed protein profiling-brief report. Arterioscler. Thromb. Vac. Biol. 33:1635-1638.

Writing, WGftWsHII. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333.